The EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended authorizations for five new medicines this week, reflecting continued pharmaceutical innovation. Concurrently, the agency initiated re-examination of Eli Lilly’s Alzheimer’s drug Kisunla, underscoring the evolving regulatory scrutiny in neurodegenerative conditions. These developments highlight ongoing shifts in European pharmaceutical approvals with implications for market access and patient care pathways.